May 11, 2021

Financial Summary(For the fiscal year ended March 31, 2021)[Under Japanese GAAP](Consolidated)
Listed Company: Zeria Pharmaceutical Co., Ltd.
(Stock Exchange: First Section of Tokyo Stock Exchange)
Code Number: 4559
(URL: https://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division
TEL (03) 3661-1039
Scheduled date of ordinary general meeting of shareholders: June 29, 2021
Scheduled date to commence dividend payments: June 30, 2021
Scheduled date to submit the Securities Report: June 29, 2021
Preparation of supplementary documents to the financial results:
Yes
Holding of financial results presentation:
Yes (for analysts, institutional investors and the press)(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2020 through March 31, 2021)(Percentage figures indicate changes from the previous year.)(1) Consolidated Financial Results
Net salesYear ended
March 31, 2021
March 31, 2020

Million yen
55,44260,426

Operating profit%
(8.2)
(2.3)

Million yen
3,4424,094%(15.9)
9.6

Profit attributable toowners of parent
Million yen%
3,119
6.6
2,925
(15.3)

Ordinary profit
Million yen
3,175
3,879%(18.2)
17.7

Note: Comprehensive income: For the year ended March 31, 2021: 6,226 million yen [ – %]For the year ended March 31, 2020: (1,471) million yen [ – %]Year ended
March 31, 2021
March 31, 2020

Basic earnings
per share
Yen
67.72
62.62

Diluted earnings
per share
Yen––Ordinary profit
to total assets

Return on equity%%

5.7
5.2

2.8
3.6

Operating profit
to net sales%
6.2
6.8

Reference: Share of profit (loss) of entities accounted for using equity method: For the year ended March 31, 2021: − million yen
For the year ended March 31, 2020: − million yen(2) Consolidated Financial Position
Total assets
As ofMarch 31, 2021
March 31, 2020

Net assets

Million yen
121,859
104,155

Equity ratio

Million yen
56,17952,678Reference: Equity: As of March 31, 2021: 56,012 million yen

Net assets per share%Yen
1,225.69
1,134.30

Cash flows fromfinancing activities
Million yen
11,185(5,877)

Cash and cash equivalents
at the end of term
Million yen
9,668
8,880

46.0
50.4

As of March 31, 2020: 52,510 million yen(3) Consolidated Cash Flows

Year ended
March 31, 2021
March 31, 2020

Cash flows fromoperating activities
Million yen
6,894
7,251

Cash flows frominvesting activities
Million yen(17,460)(405)

2. Dividends
Annual dividends

Year ended
March 31, 2020
March 31, 2021
Year ending
March 31, 2022
(Forecast)Firstquarter
Yen––

Secondquarter
Yen
17.00
17.00

Thirdquarter
Yen–––

17.00–

Year-end

Total

Totaldividends paid(Total)

Yen
17.00
17.00

Yen
34.00
34.00

Million yen
1,576
1,561

17.00

34.00

Payout ratio(Consolidated)

Dividend ratefor net assets(Consolidated)

%
54.3
50.2%
2.9
2.9

47.1

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2022 (April 1, 2021 through March 31, 2022)(Percentage figures indicate changes from the same period of the previous year.)
BasicNet sales
Operating profit
Ordinary profit
Profitearnings pershare
Million yen%
Million yen%
Million yen%
Million yen%
YenFirst six months
29,000–2,100–
2,200–
1,500–
32.82
Full year
60,000–4,800–
4,800–
3,300–
72.21
Note: The “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29) and its related implementation guidance will beapplied from the start of the fiscal year ending March 31, 2022. Accordingly, the figures presented above for consolidated forecasts
reflect the application of the aforementioned accounting standard, etc. and year-on-year comparisons have been omitted.

* Notes(1) Significant changes of subsidiaries during the fiscal year ended March 31, 2021 (changes in specified subsidiaries resulting
in changes in scope of consolidation): None
Inclusion: – (Company name: –)Exclusion: – (Company name: –)(2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements aftererror corrections
1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(3) Number of shares issued (common shares)
1) Number of shares issued as of the end of the term (including treasury shares):
As of March 31, 2021: 53,119,190 shares
As of March 31, 2020: 53,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
As of March 31, 2021: 7,420,461 shares
As of March 31, 2020: 6,825,944 shares
3) Average number of shares during the term:
For the year ended March 31, 2021: 46,071,761 shares
For the year ended March 31, 2020: 46,714,006 sharesReference: Summary of Non-consolidated Financial Results
Non-consolidated Financial Highlights (April 1, 2020 through March 31, 2021)(Percentage figures indicate changes from the previous year.)(1) Non-consolidated Financial Results
Net salesYear ended
March 31, 2021
March 31, 2020

Operating profit

Million yen
33,99940,545%(16.1)(5.6)

Basic earnings
per share
Year ended
March 31, 2021
March 31, 2020

Million yen
356
1,816

Ordinary profit%(80.4)
17.4

Million yen
1,055
2,880

Profit%(63.4)
9.2

Million yen
1,250
1,889%(33.8)(47.3)

Diluted earnings
per share

Yen
27.14
40.46

Yen––(2) Non-consolidated Financial Position
Total assets
As ofMarch 31, 2021
March 31, 2020

Million yen
95,014
83,055

Reference: Equity: As of March 31, 2021: 41,356 million yen

Net assets

Equity ratio

Million yen
41,35642,234

Net assets per share%

43.5
50.9

Yen
904.99912.32As of March 31, 2020: 42,234 million yen* Financial Summary Is Not Required to Be Audited by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters
The description about the future including the projection in this document is based on information available to theCompany at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions
herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ
from the information in this document due to various factors.